Author: Alisha G C

Abstract

B-cell maturation antigen (BCMA) has emerged as one of the most promising therapeutic targets in multiple myeloma due to its selective expression on plasma cells and critical role in tumor survival signaling. Several innovative immunotherapies targeting BCMA have recently transformed the treatment landscape of relapsed or refractory multiple myeloma (RRMM). These include bispecific antibodies such as Teclistamab, chimeric antigen receptor T-cell (CAR-T) therapies including Idecabtagene vicleucel and Ciltacabtagene autoleucel, and antibody-drug conjugates such as Belantamab mafodotin. Each therapeutic modality uses a distinct mechanism to eliminate malignant plasma cells while overcoming resistance to conventional therapies such as proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies. This review provides a comprehensive comparison of BCMA-targeted therapies, focusing on their molecular design, mechanisms of action, clinical efficacy, safety profiles, and emerging resistance mechanisms.

Introduction

Multiple myeloma is a malignant plasma cell disorder characterized by clonal expansion of antibody-producing plasma cells within the bone marrow. Despite advances in treatment using proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies, most patients eventually develop relapsed or refractory disease.

Recent progress in cancer immunotherapy has identified BCMA (B-cell maturation antigen) as a highly effective therapeutic target.

BCMA is expressed almost exclusively on:

• Plasma cells

• Malignant myeloma cells

Importantly, it plays a crucial role in plasma cell survival by interacting with its ligands BAFF and APRIL, which activate intracellular pathways such as:

• NF-κB signaling

• PI3K–AKT pathway

• MAP kinase signaling

Because of its restricted expression and biological importance, BCMA has become the focus of several next-generation immunotherapies.

Three major BCMA-targeted therapeutic classes have emerged:

1. Bispecific antibodies

2. CAR-T cell therapies

3. Antibody-drug conjugates

Each approach uses a unique strategy to destroy malignant plasma cells.

Bispecific Antibodies Targeting BCMA

In BCMA-targeted therapy, these antibodies bind:

• BCMA on myeloma cells

• CD3 on T cells

This dual binding brings cytotoxic T lymphocytes into direct contact with tumor cells and triggers immune-mediated killing.

Teclistamab

Teclistamab is a BCMA × CD3 bispecific IgG4 antibody designed to redirect T cells toward malignant plasma cells.

Once both targets are engaged:

1. T-cell receptor clustering occurs

2. T cells become activated

3. Cytotoxic granules containing perforin and granzyme B are released

4. Tumor cells undergo apoptosis

Unlike CAR-T therapy, Teclistamab uses the patient’s existing T cells without genetic modification.

Advantages of Bispecific Antibodies

• Off-the-shelf therapy

• No complex manufacturing

• Repeat dosing possible

• Rapid treatment initiation

Limitations

• Cytokine release syndrome

• Risk of infection due to immune suppression

• Possible antigen escape

CAR-T Cell Therapy Targeting BCMA

Chimeric antigen receptor T-cell (CAR-T) therapy represents one of the most advanced forms of personalized cancer immunotherapy.

In this approach:

1. T cells are collected from the patient.

2. These cells are genetically engineered to express a CAR receptor targeting BCMA.

3. The modified cells are expanded in the laboratory.

4. CAR-T cells are infused back into the patient.

Once infused, CAR-T cells recognize BCMA-expressing tumor cells and trigger strong cytotoxic immune responses.

Two BCMA CAR-T therapies have shown remarkable clinical success.

Idecabtagene Vicleucel (Abecma)

This CAR-T therapy demonstrated high response rates in heavily pretreated patients.

Key clinical findings include:

• Overall response rate ~73%

• Median progression-free survival ~8–9 months

Ciltacabtagene Autoleucel (Carvykti)

Ciltacabtagene autoleucel has demonstrated even higher response rates.

Clinical trials reported:

• Overall response rate >95%

• Deep and durable responses in many patients

Advantages of CAR-T Therapy

• Extremely high response rates

• Potential for long-term remission

• Single infusion therapy

Limitations

• Complex manufacturing process

• Long production time

• High treatment cost

• Risk of severe cytokine release syndrome and neurotoxicity

Antibody-Drug Conjugates Targeting BCMA

Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the cytotoxic potency of chemotherapy.

These molecules consist of three components:

1. Monoclonal antibody targeting BCMA

2. Cytotoxic drug payload

3. Chemical linker

After binding BCMA:

1. The ADC is internalized into the tumor cell.

2. The linker is cleaved.

3. The cytotoxic payload is released.

4. Tumor cell death occurs.

Belantamab Mafodotin

Belantamab mafodotin was the first BCMA-targeted ADC approved for multiple myeloma.

Its cytotoxic payload monomethyl auristatin F (MMAF) disrupts microtubule formation and induces apoptosis.

Advantages of Antibody-Drug Conjugates

• Direct tumor killing

• No reliance on immune activation

• Simpler administration compared with CAR-T therapy

Limitations

• Ocular toxicity (keratopathy)

• Lower response rates compared with CAR-T therapies

• Potential drug resistance

Comparison of BCMA-Targeted Therapies

Resistance Mechanisms in BCMA-Targeted Therapies

Despite impressive responses, resistance remains a major challenge.

BCMA Antigen Loss

Tumor cells may reduce or eliminate BCMA expression, preventing immune recognition.

Mechanisms include:

• Genetic mutations

• Alternative splicing

• Shedding of soluble BCMA

T-Cell Dysfunction

Chronic immune activation can lead to T-cell exhaustion, characterized by:

• Increased PD-1 expression

• Reduced cytokine production

• Impaired cytotoxicity

Immunosuppressive Bone Marrow Microenvironment

The myeloma bone marrow niche contains suppressive immune cells including:

• Regulatory T cells

• Myeloid-derived suppressor cells

• Tumor-associated macrophages

These cells produce inhibitory cytokines that dampen anti-tumor immune responses.

Emerging BCMA-Targeted Strategies

Next-generation therapies are being developed to improve treatment durability.

Dual-Target Bispecific Antibodies

New agents target multiple plasma cell antigens simultaneously, such as:

• BCMA + GPRC5D

• BCMA + FcRH5

This strategy reduces antigen escape.

Combination Immunotherapy

Combining BCMA therapies with:

• Checkpoint inhibitors

• Immunomodulatory drugs

• Cytokine therapies

may improve T-cell function and persistence.

Future Directions

The future of multiple myeloma treatment will likely involve combination immunotherapy approaches integrating:

• Bispecific antibodies

• CAR-T cell therapy

• Antibody-drug conjugates

• Immune checkpoint inhibitors

Advances in immune engineering and molecular profiling will enable personalized treatment strategies for patients with relapsed or refractory disease.

Conclusion

BCMA-targeted therapies have revolutionized the treatment of multiple myeloma by providing highly effective immunotherapeutic options for patients with refractory disease. Bispecific antibodies such as Teclistamab enable rapid off-the-shelf immune redirection, while CAR-T cell therapies offer deep and durable responses through engineered cellular immunity. Antibody-drug conjugates provide a complementary approach by delivering potent cytotoxic agents directly to tumor cells. Continued research aimed at overcoming resistance mechanisms and optimizing combination strategies will be critical for improving long-term outcomes and achieving durable remissions in multiple myeloma.

Frequently Asked Questions (FAQ)

Q1. What is BCMA and why is it important in multiple myeloma?
BCMA is a plasma cell surface receptor that regulates survival signaling and is highly expressed on malignant myeloma cells, making it an ideal therapeutic target.

Q2. What are the three major BCMA-targeted therapies?
The main classes include bispecific antibodies, CAR-T cell therapy, and antibody-drug conjugates.

Q3. Which BCMA therapy is most effective?
CAR-T therapies currently show the highest response rates, but bispecific antibodies offer faster and more accessible treatment.

Q4. What are the major side effects of BCMA immunotherapy?
Common toxicities include cytokine release syndrome, infections, neurotoxicity, and ocular toxicity depending on the therapy type.

Q5. Can patients receive multiple BCMA therapies?
Yes, sequential or combination therapies are being explored to overcome resistance and improve outcomes.